Bicycle Therapeutics Plc ADR

BCYCNASDAQ · USD
3.20USD0.00 (+0.63%)
652

Bicycle Therapeutics Plc ADR (BCYC) Option Chain

Read more

Tracking the BCYC option chain helps you see every strike and expiry on Bicycle Therapeutics Plc ADR in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of BCYC options activity at a glance. Use our scanner to monitor the BCYC option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For BCYC stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where BCYC options are being actively traded, and where they are not.

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase.

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
0.02000.352.200.105.001.00-68.75—4.900.004.900099.98
8.86003.701.20—4.902.00-37.50—1.000.001.000091.14
47.95101.150.20—1.353.00-6.25—0.050.000.0503052.05
80.771,11904.900.00—4.904.00+25.00—1.000.800.20016719.23
94.341204.900.00—4.905.00+56.250.104.901.800.70005.66

As of Nov 17, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank86.11% High
  • Market cap (M$)162
  • 52 weeks high-59.13%
  • 52 weeks low4.23%
  • Analyst recommendationBuy
    1.60
  • Target price$9.86
    208.13% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-10-29
  • P/E—
  • Future P/E—
  • EPS (ttm)-2.03
  • EPS growth next 5 years6.75%

As of Nov 17, 2026